-
1
Granulocyte transfusions have been debated for over 50 years regarding their effectiveness in reducing infection risk in patients with low granulocyte counts.
-
2
Research indicates that the threshold for increased infection risk may be lower than previously thought, potentially between 0 and 0.2 × 10E + 9/L.
-
3
A large randomized controlled trial found that granulocyte transfusions did not improve infection rates, remission, or survival in AML patients undergoing chemotherapy.
-
4
Post-study, the use of prophylactic granulocyte transfusions significantly declined, suggesting a consensus against their routine use in certain patient populations.
-
5
Despite historical interest, granulocyte transfusions remain a niche practice, with limited clinical trial activity and ongoing debate about their utility.
